Compositions of the ethyl ester of L-DOPA
July 18, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3803120 Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease Effervescent enteric coated L-dopa formulation and method of using the same Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease Rectally absorbable form of L-dopa Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof Method of treating parkinson's syndrome Patent #: 4916151 InventorsAssignee
ApplicationNo. 276196 filed on 07/18/1994US Classes:514/567, Benzene ring nonionically bonded514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/654, The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only560/43, The nitrogen is bonded directly to a ring and is in same side chain as ester function560/45, Oxy in acid moiety562/433, Nitrogen bonded directly to carbon of organic radical (e.g., amino acids, etc.)562/445Phenyl alaninesExaminersPrimary: Criares, Theodore J.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/195A61K 031/135 C07C 229/00 AbstractA composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester derived from its crystaline form in an amount which is at least 97%, by weight, of the active ingredient, and L-DOPA in an amount which is less than 1% by weight of such active ingredient is provided by this invention. This invention also provides a process for preparing such a composition. Further, this invention provides a method of treating a patient suffering from Parkinson's disease which comprises administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of L-DOPA ethyl ester derived from its crystaline form and a pharmaceutically acceptable carrier.Other References
Field of SearchBenzene ring nonionically bondedAmino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only The nitrogen is bonded directly to a ring and is in same side chain as ester function Oxy in acid moiety Nitrogen bonded directly to carbon of organic radical (e.g., amino acids, etc.) Phenyl alanines |
| ||||||||||||||
